Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Jul 19 2016

• By Cathy Kelly

Express Scripts HQ

Related Content

Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk

Jul 15 2016

CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016

Mar 04 2016

Rx Spending Growth Won’t Exceed 8% In Coming Years – Express Scripts

Mar 15 2016

Why There’s Still Room For Sarilumab In RA, According To Sanofi

Nov 10 2015

JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis

Nov 16 2015

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

AstraZeneca Unburdens Itself Of Brodalumab

Sep 01 2015

Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?

Jul 11 2016

Related Companies

Express Scripts Holding Company

CVS Health Corp.

Bristol Myers Squibb Company

Pfizer Inc.

Johnson & Johnson

AbbVie Inc.

Amgen, Inc.

Johnson & Johnson

Novartis AG

Eli Lilly and Company

Sanofi

Regeneron Pharmaceuticals, Inc.

Bausch Health Companies Inc.

AstraZeneca PLC

Additional Topics

United States Market Access Commercial Inflammation BioPharmaceutical

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window